About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

5 Insightful Analyst Questions From Gilead Sciences’s Q1 Earnings Call

GILD Cover Image

Gilead Sciences’ first quarter performance saw sales remain flat year over year, which did not meet Wall Street’s revenue expectations and prompted a negative market reaction. Management attributed the quarter’s outcomes to growth in the HIV and liver disease businesses, with Biktarvy and Descovy showing strong demand. However, softness in oncology—particularly Trodelvy—and ongoing challenges in the cell therapy segment weighed on overall results. CEO Daniel O’Day acknowledged, “Year-over-year growth in our HIV and liver disease businesses was partially offset by softer than expected Trodelvy sales due to inventory dynamics that masked increase in demand, as well as headwinds in cell therapy.”

Is now the time to buy GILD? Find out in our full research report (it’s free).

Gilead Sciences (GILD) Q1 CY2025 Highlights:

  • Revenue: $6.67 billion vs analyst estimates of $6.81 billion (flat year on year, 2.1% miss)
  • Adjusted EPS: $1.81 vs analyst estimates of $1.77 (2.1% beat)
  • The company reconfirmed its revenue guidance for the full year of $28.4 billion at the midpoint
  • Management reiterated its full-year Adjusted EPS guidance of $7.90 at the midpoint
  • Operating Margin: 33.6%, up from -64.6% in the same quarter last year
  • Market Capitalization: $135 billion

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions Gilead Sciences’s Q1 Earnings Call

  • Michael Yee (Jefferies): asked about lenacapavir’s launch dynamics and reimbursement timelines. Chief Commercial Officer Johanna Mercier explained that access is expected to build gradually, with 75% coverage within six months and broader adoption by twelve months.
  • Salveen Richter (Goldman Sachs): inquired about tariff risk and manufacturing exposure. CEO Daniel O’Day clarified that most intellectual property and manufacturing are U.S.-based, reducing tariff exposure, while CFO Andrew Dickinson confirmed that cost impacts are reflected in current guidance.
  • Tyler Van Buren (TD Cowen): questioned the drivers behind Trodelvy’s lower demand. Mercier attributed it mainly to inventory fluctuations, noting the product’s strong position in breast cancer indications.
  • Tim Anderson (BofA): asked if lenacapavir for PrEP would cannibalize Descovy sales. Mercier indicated initial uptake would be from both switch and new patients, but declined to provide specific cannibalization estimates.
  • Evan Seigerman (BMO): asked about competitive dynamics in cell therapy. Kite’s Cindy Perettie explained that both bispecifics and in-class products are contributing to increased competition, especially outside the U.S.

Catalysts in Upcoming Quarters

In upcoming quarters, the StockStory team will be monitoring (1) the FDA’s decision and subsequent adoption curve for lenacapavir in HIV prevention, (2) regulatory progress and commercial momentum for Livedelzi in international markets, and (3) updates on Trodelvy’s label expansion and anetocel’s clinical development. Execution on these launches and adaptation to evolving reimbursement policies will be critical for Gilead’s growth trajectory.

Gilead Sciences currently trades at $109.15, up from $106.07 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.